You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

CLINICAL TRIALS PROFILE FOR METAXALONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for METAXALONE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT06157177 ↗ Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Recruiting Illumination Health Phase 4 2023-11-15 The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: - Amount and quality of pain - Interference with physical activity - Interference with sleep
NCT06157177 ↗ Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Recruiting Primus Pharmaceuticals Phase 4 2023-11-15 The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: - Amount and quality of pain - Interference with physical activity - Interference with sleep
NCT04003350 ↗ The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty Completed Rothman Institute Orthopaedics N/A 2017-12-21 It is well recognized that a multimodal analgesia program targeting multiple pain pathways, is more effective for controlling pain during the hospital stay and in the acute postoperative period than monotherapy-based regimens, such as opioids only. This multimodal analgesic regimen also leads to reduce opioid consumption and its related side effects after hip and knee joint replacement procedures. One potential strategy to reduce the use of opioids after TKA is to administer a prolonged oral multimodal pain regimen that targets multiple pain pathways in the post hospital discharge period. This can be equal or more effective than the regimen of opioid prescriptions used after TKA. To the best of our knowledge, there have been no studies conducted that directly examine the effect of prolonged multimodal pain regimen after hospital discharge in primary TKA patients. PURPOSE: 1. To determine whether a prolonged multimodal pain regimen after discharge from primary TKA can provide equivalent or better pain control while reducing opioid consumption and, subsequently, opioid-related side effects. 2. To determine whether patient expectations and routine opioid prescription practices at the time of discharge from primary TKA impacts opioid consumption.
NCT03068897 ↗ Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain Completed Montefiore Medical Center Phase 4 2017-05-03 This is a randomized study, based in emergency departments, in which the investigators determine the utility of adding various skeletal muscle relaxants to standard therapy, which consists of ibuprofen and an educational session. Patients will be enrolled at the time of an emergency visit and followed for three months to determine outcomes.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for METAXALONE

Condition Name

11110-0.100.10.20.30.40.50.60.70.80.911.1Low Back PainLumbar Spinal StenosisOsteo Arthritis KneeSciatica Acute[disabled in preview]
Condition Name for METAXALONE
Intervention Trials
Low Back Pain 1
Lumbar Spinal Stenosis 1
Osteo Arthritis Knee 1
Sciatica Acute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

11110-0.100.10.20.30.40.50.60.70.80.911.1Back PainSpinal StenosisSciaticaConstriction, Pathologic[disabled in preview]
Condition MeSH for METAXALONE
Intervention Trials
Back Pain 1
Spinal Stenosis 1
Sciatica 1
Constriction, Pathologic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for METAXALONE

Trials by Country

+
Trials by Country for METAXALONE
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for METAXALONE
Location Trials
Virginia 1
Texas 1
Ohio 1
North Carolina 1
New Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for METAXALONE

Clinical Trial Phase

66.7%33.3%0-0.200.20.40.60.811.21.41.61.822.2Phase 4N/A[disabled in preview]
Clinical Trial Phase for METAXALONE
Clinical Trial Phase Trials
Phase 4 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

66.7%33.3%0-0.200.20.40.60.811.21.41.61.822.2CompletedRecruiting[disabled in preview]
Clinical Trial Status for METAXALONE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for METAXALONE

Sponsor Name

trials000001111111Montefiore Medical CenterRothman Institute OrthopaedicsIllumination Health[disabled in preview]
Sponsor Name for METAXALONE
Sponsor Trials
Montefiore Medical Center 1
Rothman Institute Orthopaedics 1
Illumination Health 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

75.0%25.0%000.511.522.53OtherIndustry[disabled in preview]
Sponsor Type for METAXALONE
Sponsor Trials
Other 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

METAXALONE Market Analysis and Financial Projection

Metaxalone: Clinical Trials, Market Analysis, and Projections

Introduction to Metaxalone

Metaxalone is a muscle relaxant medication used to treat musculoskeletal pain and spasms. It works by blocking nerve impulses in the brain, providing relief from conditions such as bone pain, muscle pain, tunnel syndrome, and joint pain. Here’s a comprehensive update on the clinical trials, market analysis, and projections for metaxalone.

Clinical Trials and Development

While metaxalone itself is not currently in active clinical trials for new indications, it is important to note that the drug has already been approved by the FDA and is widely used. However, the landscape of muscle relaxants and related treatments is continually evolving.

Current Market Context

The metaxalone market is influenced by several factors, including the prevalence of musculoskeletal disorders, the number of road accidents, and the growing geriatric population.

Market Analysis

Market Size and Growth

The global metaxalone market is projected to grow significantly over the next few years. By 2026, the market size is estimated to reach $5,770 million, growing at a CAGR of 6% during the 2021-2026 forecast period[2][3].

Segmentation by Indication

The metaxalone market can be segmented by indication into several key areas:

  • Bone Pain: This segment accounted for the largest share in 2020, driven by increasing cases of arthritis and other musculoskeletal conditions.
  • Muscle Pain: Expected to register the fastest CAGR of 2.5% during the 2021-2026 period, due to its widespread use in treating muscle spasms and musculoskeletal pain.
  • Joint Pain: This segment is expected to register a reasonable growth rate, influenced by the prevalence of unhealthy lifestyles and increasing outdoor activities.
  • Tunnel Syndrome: Although tunnel syndrome can be cured, the lingering symptoms ensure a steady demand for metaxalone, contributing to a healthy growth rate[2][3].

Segmentation by End-Use Industry

The market is also segmented by end-use industry:

  • Hospitals: Dominated the market in 2020 due to easy accessibility and higher selling capacity.
  • Clinics: Expected to register a CAGR of 1.5% over 2021-2026, driven by extended operating hours and fast service[2][3].

Geographical Analysis

  • North America: Held a major share of 40% in 2020, driven by an advanced healthcare system and significant developments in the pharmaceutical industry.
  • Asia Pacific: Expected to outpace other regions with the highest CAGR during the forecast period, due to a rising population and increasing healthcare development[2][3].

Market Drivers

Growing Musculoskeletal Disorders

The increasing number of musculoskeletal disorders among people, particularly arthritis, is a major driver for the metaxalone market. Unhealthy lifestyles and the growing geriatric population also contribute to this trend[2][3].

Road Accidents and Outdoor Activities

Road accidents and the rise in outdoor activities, such as sports and gymnasiums, increase the demand for metaxalone. However, the COVID-19 pandemic temporarily reduced this demand due to lockdowns and reduced outdoor activities[2][3].

Pharmaceutical Industry Development

The expansion of the pharmaceutical industry, especially in regions like Italy, provides multiple growth opportunities for metaxalone. Increasing research and development activities further enhance market demand[2][3].

Market Challenges

Increasing Side Effects

One of the significant challenges facing the metaxalone market is the increasing side effects associated with the drug, such as vomiting, headache, nausea, and irritability. These side effects can deter consumers and create hurdles for market growth[2][3].

Stringent Government Approvals

Stringent government regulations and approval processes can also impede the growth of the metaxalone market. The need for a doctor's prescription and strict drug prescribing laws add to these challenges[2][3].

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the metaxalone market. Lockdowns reduced road accidents and outdoor activities, thereby decreasing the demand for metaxalone. However, as lockdowns were lifted and normal activities resumed, the market began to recover[2][3].

Future Projections

Market Growth

The metaxalone market is expected to continue growing, driven by the increasing prevalence of musculoskeletal disorders and the growing geriatric population. The market is projected to reach significant heights by 2026 and beyond[2][3].

Regional Expansion

Asia Pacific is expected to be a key region for growth, with a rising population and increasing healthcare development. North America will continue to be a significant market due to its advanced healthcare system and ongoing pharmaceutical developments[2][3].

Research and Development

Ongoing research and development in the pharmaceutical industry will continue to drive the market. New formulations and improved versions of metaxalone could enhance safety, efficacy, and tolerability, further boosting market growth[2][3].

Key Takeaways

  • Market Size: The global metaxalone market is projected to reach $5,770 million by 2026.
  • Growth Drivers: Increasing musculoskeletal disorders, road accidents, and outdoor activities.
  • Challenges: Side effects and stringent government approvals.
  • COVID-19 Impact: Temporary reduction in demand due to lockdowns, with recovery as normal activities resumed.
  • Future Projections: Continued growth driven by demographic and healthcare trends.

FAQs

What is the current market size of the metaxalone market?

The current market size of the metaxalone market is estimated to reach $5,770 million by 2026, growing at a CAGR of 6% during the 2021-2026 forecast period[2][3].

What are the main drivers of the metaxalone market?

The main drivers include the growing number of musculoskeletal disorders, road accidents, and increasing outdoor activities, as well as the expansion of the pharmaceutical industry[2][3].

How did the COVID-19 pandemic affect the metaxalone market?

The COVID-19 pandemic had a negative impact due to lockdowns reducing road accidents and outdoor activities, but the market has started to recover as normal activities resumed[2][3].

What are the major challenges facing the metaxalone market?

The major challenges include increasing side effects associated with the drug and stringent government approvals and regulations[2][3].

Which region is expected to drive the growth of the metaxalone market in the future?

Asia Pacific is expected to drive the growth of the metaxalone market, with North America continuing to be a significant market due to its advanced healthcare system[2][3].

What is the outlook for the metaxalone market in terms of research and development?

Ongoing research and development are expected to drive the market, with potential new formulations and improved versions of metaxalone enhancing safety, efficacy, and tolerability[2][3].

Sources

  1. IndustryARC: Metaxalone Market Size Report, 2021-2026.
  2. MarketDataForecast: Metaxalone Market Size, Share & Growth Report, 2032.
  3. 6Wresearch: Mali Metaxalone Market (2024 - 2029) | Trends, Outlook & Forecast.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.